江西富祥药业股份有限公司 非经营性资金占用及其他关联资金 往来情况的专项报告 2024年度 关于江西富祥药业股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2025]第 ZF10361 号 江西富祥药业股份有限公司全体股东： 我们审计了江西富祥药业股份有限公司(以下简称"贵公 司")2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司 资产负债表、2024 年度合并及母公司利润表、合并及母公司现金流量 表、合并及母公司所有者权益变动表和相关财务报表附注，并于 2025 年 4 月 24 日出具了报告号为信会师报字[2025]第 ZF10358 号的无保 留意见审计报告。 贵公司管理层根据中国证券监督管理委员会《上市公司监管指引 第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公告 〔2022〕26 号）和《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》的相关规定编制了后附的 2024 年度非经营性资 金占用及其他关联资金往来情况汇总表（以下简称"汇总表"）。 编制汇总表并确保其真实、准确、合法和完整是贵公司管理层的 责任。我 ...

证券代码：300497 证券简称：富祥药业 公告编号：2025-027 江西富祥药业股份有限公司 3、投资品种 为控制风险，公司闲置自有资金用于购买安全性高、流动性好的短期、低风险理 财产品或结构性存款。 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司（以下简称"公司"）于2025年4月24日召开的第四 届董事会第二十七次会议及第四届监事会第十七次会议审议通过了《关于使用部分闲 置自有资金进行现金管理的议案》，为提高公司资金使用效率，合理利用自有资金， 获取较好的投资回报，在保证日常经营资金需求和资金安全的前提下，公司拟用不超 过人民币2亿元的闲置自有资金进行现金管理，购买期限不超过12个月的银行或其他 金融机构的投资产品（包括但不限于协定存款、结构性存款、国债逆回购等），在上 述额度及决议有效期内，资金可以滚动使用。 一、使用闲置自有资金进行现金管理的情况 1、管理目的 为提高公司资金使用效率，在不影响公司正常经营情况下，合理利用部分闲置自 有资金进行现金管理，增加资金收益，为公司及股东获 ...

（一）会计师事务所基本情况 立信会计师事务所（特殊普通合伙）（以下简称"立信"）由我国会计泰斗潘 序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国首家完成改制的 特殊普通合伙制会计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。 立信是国际会计网络 BDO 的成员所，长期从事证券服务业务，新证券法实施前 具有证券、期货业务许可证，具有 H 股审计资格，并已向美国公众公司会计监 督委员会（PCAOB）注册登记。 江西富祥药业股份有限公司董事会审计委员会 对会计师事务所 2024 年度履职情况评估及履行监督职责情况报告 根据《公司法》《证券法》《上市公司治理准则》《国有企业、上市公司选聘 会计师事务所管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等法律法规，现将江西富祥药业股份有限公司（以下简 称"公司"）董事会审计委员会对会计师事务所 2024 年度履职情况评估及审计委 员会履行监督职责情况的报告汇报如下： 一、2024 年年审会计师事务所基本情况 （一）审计委员会对立信的专业资质、业务能力、诚信状况、独立性、过往 审计工作情况及其执业质量等 ...

证券代码：300497 证券简称：富祥药业 公告编号：2025-033 江西富祥药业股份有限公司 关于举行2024年年度报告业绩网上说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司（以下简称"公司"）2024 年年度报告全文及其报告 摘要于 2025 年 4 月 28 日刊登于中国证监会指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）。 为了更好地与广大投资者进行交流，使投资者能够进一步了解公司的生产经营情 况，公司定于2025年5月19日（星期一）15：00-17：00在全景网举办公司2024年年度 业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者可登陆全景网 "投资者关系互动平台"（https://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长兼总经理包建华先生、独立董事刘洪先生、 财务总监杨光先生、董事会秘书彭云女士、保荐代表人梁国超先生。 为充分尊重投资者、提升交流的针对性，现就公司2024年度业绩说明会提前向投 资者公开征集问题，广 ...

江西富祥药业股份有限公司 募集资金存放与使用情况专项报告 的鉴证报告 2024年度 关于江西富祥药业股份有限公司 2024年度募集资金存放与使用情况专项报告的鉴证报告 信会师报字[2025]第ZF10360号 江西富祥药业股份有限公司全体股东： 我们接受委托，对后附的江西富祥药业股份有限公司（以下简称 "贵公司"）2024年度募集资金存放与使用情况专项报告（以下简称"募 集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 贵公司董事会的责任是按照中国证券监督管理委员会《上市公司 监管指引第2号——上市公司募集资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15号）、《深圳证券交易所上市公 司自律监管指引第2号—创业板上市公司规范运作》以及《深圳证券 交易所创业板上市公司自律监管指南第2号——公告格式》的相关规 定编制募集资金专项报告。这种责任包括设计、执行和维护与募集资 金专项报告编制相关的内部控制，确保募集资金专项报告真实、准确、 完整，不存在虚假记载、误导性陈述或重大遗漏。 二、注册会计师的责任 鉴证报告 第 1 页 四、鉴证结论 我们认为，贵公司2024年度募集资金存放 ...

江西富祥药业股份有限公司 2024 年度监事会工作报告 2024 年，江西富祥药业股份有限公司（以下简称"公司"）监事会全体成员 严格按照《公司法》《公司章程》《监事会议事规则》和有关法律法规的要求， 认真履行职责，积极开展工作，对公司经营活动、财务状况、董事和高级管理人 员履行职责的情况等事项进行监督，保障了公司、股东和员工的合法权益，促进 了公司的规范运作。现将 2024 年主要工作汇报如下： 一、2024 年监事会工作情况 （一）监事会会议召开情况 2024 年，共组织召开了四次监事会。分别是： 1、第四届监事会第十二次会议于 2024 年 3 月 22 日召开，审议通过了《关 于公司 2023 年度以简易程序向特定对象发行股票竞价结果的议案》《关于公司 与特定对象签署附生效条件的股份认购合同的议案》《关于公司<2023 年度以简 易程序向特定对象发行股票预案（修订稿）>的议案》《关于公司<2023 年度以 简易程序向特定对象发行股票方案论证分析报告（修订稿）>的议案》《关于公 司<2023 年度以简易程序向特定对象发行股票募集资金使用可行性分析报告（修 订稿）>的议案》《关于公司 2023 年度以简易 ...

江西富祥药业股份有限公司 江西富祥药业股份有限公司 2024 环境、社会及公司治理（ESG）报告 年度 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 地 址：景德镇市昌江区鱼丽工业区2号鱼山与丽阳交界处 电 话：0798-2699929 邮 箱：stock@fushine.cn 官网地址：http://www.fushine.cn/ 关于本报告 目录 走进富祥药业 ESG治理 公司治理 守责环境 共促绿色运营 创新驱动 共建品质保障 责任为重 牢筑健康安全 关于本报告 报告说明 本报告为江西富祥药业股份有限公司披露的第二份环境、社会及公司治理报告。报告详细披露公司2024年度 在经济、环境、社会及公司治理等责任领域的实践和绩效，旨在与各利益相关方进行有效交流，系统地回应 利益相关方的期望和要求。 编制依据 本报告参照《深圳证券交易所上市公司自律监管指引第17号——可持续发展报告（试行）》、中国企业社会 责任报告编写指南（CASS-ESG 6.0）、全球报告倡议组织GRI《可持续发展报告标准》（2021）、联合国可 持续发展目标（SDGs）、欧洲可持续报告准则（ESRS ...

江西富祥药业股份有限公司 2024 年度董事会工作报告 一、经营情况讨论与分析 2024 年，面对深刻变革与不确定性交织的外部环境，公司所处行业市场竞 争加剧。公司管理层以战略定力锚定发展航向，系统性推进三大业务板块协同发 展，以精细化运营深度挖掘利润空间，多措并举强化竞争优势，为穿越周期性挑 战、迈向高质量发展奠定了坚实基础。 公司始终秉持长期主义发展观，在深耕存量市场的同时，以前瞻性布局持续 培育增量空间，为可持续高质量发展锻造核心引擎。报告期内，公司实现营业收 入 117,784.66 万元，实现归属于母公司净利润-27,210.06 万元。 （一）主要业务经营情况 1、医药制造（原料药、中间体）业务 报告期内，医药市场环境复杂严峻、市场竞争激烈，公司 4-AA 等产品价格 处于低位，使得医药制造业务销售收入同比有所下降；同时医药部分产品主要原 材料 6-APA 等价格持续处于高位，挤压了公司利润空间。2024 年度，医药制造 业务实现销售收入 91,800.92 万元，占公司营业收入比重 77.94%。 2024 年 4-AA 产品和 6-APA 产品价格走势图 公司深耕医药制造业务，持续优化生产工艺 ...

Financial Performance - The company reported a revenue of RMB 1.2 billion for the fiscal year 2024, representing a year-over-year growth of 15%[32]. - The total revenue for 2024 is approximately ¥1.18 billion, a decrease of 26.83% compared to ¥1.61 billion in 2023[113]. - Revenue from the pharmaceutical manufacturing sector is ¥918 million, accounting for 77.94% of total revenue, down 30.52% from ¥1.32 billion in 2023[113]. - The company reported a net profit attributable to shareholders was -¥272,100,550.53, representing a decline of 35.51% from -¥200,800,049.29 in the previous year[37]. - The gross margin for the last quarter was reported at 45%, a slight increase from 42% in the previous quarter[32]. - The company achieved a net cash flow from operating activities of CNY 187,639,943.52, a significant increase of 389.73% compared to the previous year[134]. - The basic earnings per share for 2024 was -¥0.51, down 37.84% from -¥0.37 in 2023[37]. Market Expansion and Growth Strategies - The company plans to deepen its pharmaceutical business, expand market share, and enhance the supply chain by reducing production costs in the lithium battery electrolyte additives segment[11]. - The company aims to cultivate new growth directions in synthetic biological microbial protein products and enhance market competitiveness through new project development and customer acquisition[11]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[32]. - The company expects a revenue guidance of RMB 1.5 billion for the next fiscal year, indicating a projected growth of 25%[32]. - The company is exploring potential acquisitions to diversify its product offerings, with a budget of 500 million yuan allocated for this purpose[1]. - The company is actively expanding its business in the pharmaceutical and new energy sectors, with ongoing progress reported[166]. Research and Development - The company emphasizes the importance of R&D and market research to ensure sustainable growth and product innovation[18]. - The company is investing RMB 100 million in R&D for new technologies in antibiotic production, aiming to improve efficiency by 30%[32]. - Research and development expenses decreased by 23.39% to approximately ¥74.66 million, reflecting a strategic focus on cost management[130]. - The company has successfully passed the registration application for multiple active pharmaceutical ingredients, including Ceftazidime and Paroxetine, and is moving towards commercial production[131]. Operational Efficiency and Cost Management - The company is focusing on optimizing production processes and expanding new products to enhance profitability in the pharmaceutical sector[48]. - The company is working towards the national health commission's new food raw material registration for its microbial protein products to achieve large-scale sales domestically and internationally[161]. - The company is focusing on cost control across the entire industry chain to improve production efficiency and reduce procurement costs[163]. - The company reported a 10% reduction in operational costs due to improved supply chain management[1]. Compliance and Governance - The company has established a compliance management system to enhance its competitive edge and ensure high-quality development[165]. - The board of directors consists of 7 members, including 3 independent directors, and held 8 meetings during the reporting period[172]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors[177]. - The company has established a remuneration committee to align compensation with performance metrics, ensuring accountability[195]. Market Trends and Industry Insights - The global active pharmaceutical ingredient market was valued at USD 204 billion in 2022, with a compound annual growth rate of 6% over the past six years, indicating a robust growth outlook for the pharmaceutical industry[62]. - The antibiotic market in China reached a scale of 194.5 billion yuan in 2022, with an overall growth rate of over 4%[63]. - The global demand for new energy vehicles is rapidly increasing, driving growth in the lithium battery industry and boosting the demand for electrolyte additives[102]. - The market for alternative proteins is projected to reach at least $290 billion by 2035, with microbial fermentation protein expected to capture 22% of the market share[73]. Challenges and Risks - The pharmaceutical business revenue declined due to a complex market environment and intense competition, with some product prices at low levels, impacting profit margins[7]. - The company faces risks related to market competition, environmental regulations, and raw material price fluctuations, which could impact its operations[14][15][19]. - The company has received a public reprimand from the Shenzhen Stock Exchange on May 12, 2022, for incomplete disclosure of business orders and R&D investments[194]. - The company has faced regulatory scrutiny regarding its information disclosure practices, which may impact investor confidence[194].

Financial Performance - The company's revenue for Q1 2025 was ¥233,698,855.18, a decrease of 31.35% compared to ¥340,430,593.83 in the same period last year[5] - Net profit attributable to shareholders increased by 52.46% to ¥2,238,811.99 from ¥1,468,451.11 year-on-year[5] - The net profit after deducting non-recurring gains and losses was -¥22,599,640.05, a decline of 125.95% compared to -¥10,002,144.60 in the previous year[5] - The net cash flow from operating activities decreased by 49.54% to ¥36,649,453.97 from ¥72,636,084.28 year-on-year[5] - Total operating revenue decreased to ¥233.70 million from ¥340.43 million, a decline of approximately 31.4% year-over-year[26] - Total operating costs decreased to ¥253.59 million from ¥347.98 million, a decline of approximately 27.1% year-over-year[26] - Net profit for the period was ¥609,294.47, compared to a net loss of ¥739,909.51 in the previous period[27] - Basic earnings per share increased to ¥0.004 from ¥0.003, reflecting improved profitability[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,523,478,894.49, a slight decrease of 0.30% from ¥4,536,876,135.82 at the end of the previous year[5] - The company's total assets amounted to ¥4.52 billion, slightly down from ¥4.54 billion in the previous period[25] - Current liabilities increased to ¥1.59 billion from ¥1.54 billion, an increase of approximately 3.5%[25] - Non-current liabilities decreased to ¥736.45 million from ¥816.11 million, a decline of approximately 9.8%[25] - The company's equity attributable to shareholders increased to ¥2.18 billion from ¥2.18 billion, a slight increase of approximately 0.2%[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 23,084[10] - The largest shareholder, Bao Jianhua, holds 19.71% of the shares, totaling 108,399,908 shares, with 48,250,000 shares pledged[10] - The second-largest shareholder, Yu Wenjun, holds 2.40% of the shares, totaling 13,216,446 shares[10] - The top 10 shareholders collectively hold significant stakes, with the first four shareholders accounting for over 25% of total shares[10] - The company has a total of 81,299,931 restricted shares held by Bao Jianhua, which are subject to a 25% annual unlock[13] - Yu Wenjun has 14,271,846 restricted shares, with 2,574,362 shares released this period[13] - The company has no preferred shareholders or changes in restricted shares reported for this period[12] - The company is actively managing its shareholder structure, with several shareholders involved in margin trading[11] - The total number of unrestricted shares held by the top shareholders indicates a stable ownership structure[10] - The company plans to continue monitoring shareholder activities and potential changes in ownership dynamics[11] Government Subsidies and Other Income - The company received government subsidies amounting to ¥28,417,659.14, contributing to the increase in other income by 142.36% to ¥29,050,274.30[6][8] - The company reported a significant increase in other income to ¥29.05 million from ¥11.99 million, an increase of approximately 142.5% year-over-year[27] Cash Flow and Investments - Cash inflow from financing activities increased to CNY 431,733,544.80, compared to CNY 315,595,758.00 in the previous period, marking a growth of 36.9%[30] - Net cash flow from financing activities was CNY 90,709,294.03, a recovery from a negative CNY -57,570,807.00 in the prior period[30] - The ending cash and cash equivalents balance was CNY 518,054,192.40, slightly down from CNY 555,983,540.27 at the end of the previous period[30] - The company received CNY 30,000,000.00 from investment recoveries during the period, with no such cash inflow in the previous period[30] - Cash outflow from investment activities totaled CNY 157,617,607.76, significantly higher than CNY 41,378,193.02 in the previous period[30] - Net cash flow from investment activities was negative at CNY -127,367,314.51, worsening from CNY -41,323,477.94 in the prior period[30] - Operating cash inflow for the period was CNY 236,783,629.08, down 22.3% from CNY 304,980,495.21 in the previous period[29] - Cash received from tax refunds was CNY 3,343,827.63, a significant drop of 96.2% compared to CNY 86,914,099.94 in the previous period[29] - The company reported a decrease in cash received from sales of goods and services to CNY 176,922,586.12, down 12.6% from CNY 202,523,944.62[29] Product Development and Market Strategy - The company’s main products faced price declines and decreased sales, leading to a year-on-year revenue drop, but cost reductions and increased government subsidies contributed to net profit growth[16] - The company’s product "未冉蛋白" successfully passed Self-GRAS certification, allowing it to be marketed in the U.S. as a safe food ingredient[16] - The company aims to enhance its market position in pharmaceuticals, new energy materials, and microbial protein production, focusing on strategic development across three major business segments[16] - The company plans to implement technical innovations and process optimizations to reduce production costs and improve gross margins in pharmaceutical products[18] - The company will expand the scale of lithium battery electrolyte additives to enhance market competitiveness and increase market share[18] - The company is committed to achieving rapid growth in its microbial protein business and aims for large-scale domestic and international sales of "未冉蛋白"[18] Cash and Inventory Management - The cash and cash equivalents increased by 100.59% to ¥145,855.95, reflecting the overall impact of various factors[8] - Accounts receivable decreased from CNY 261.24 million to CNY 234.85 million, indicating improved collection efficiency[23] - Inventory increased from CNY 421.05 million to CNY 444.53 million, reflecting potential growth in production or sales strategies[23]